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Abstract 
Background: The p73 protein is a tumor suppressor that shares structural and functional similarity with p53. p73 is 
expressed in two major isoforms; the TA isoform that interacts with p53 pathway, thus acting as tumor suppressor and 
the N‑terminal truncated ΔN isoform that inhibits TAp73 and p53 and thus, acts as an oncogene.
Results: By employing a drug repurposing approach, we found that protoporphyrin IX (PpIX), a metabolite of ami‑
nolevulinic acid applied in photodynamic therapy of cancer, stabilizes TAp73 and activates TAp73‑dependent apopto‑
sis in cancer cells lacking p53. The mechanism of TAp73 activation is via disruption of TAp73/MDM2 and TAp73/MDMX 
interactions and inhibition of TAp73 degradation by ubiquitin ligase Itch. Finally, PpIX showed potent antitumor effect 
and inhibited the growth of xenograft human tumors in mice.
Conclusion: Our findings may in future contribute to the successful repurposing of PpIX into clinical practice.
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Background
Drug repurposing brings hope for the improved treat-
ment of cancer patients due to the financial toxicity of 
current cancer care that impacts both, patient care and 
healthcare system worldwide [1].
p73 and p63 are structural and functional homologs of 
the p53 tumor suppressor protein. All p53 family proteins 
share the ability to activate p53 target genes involved in 
apoptosis and cell cycle control under stress conditions.
The TP73 gene structure is complex due to the exist-
ence of two alternative promoters (P1 and P2) (Fig. 1a). 
The P1 promoter drives the expression of transcription-
ally active TAp73 isoforms, acting as tumor suppressors, 
while expression from P2 promoter generates N-terminal 
truncated ΔNp73 isoforms, acting as dominant negative 
towards TA isoforms and p53 proteins, and thus known 
as oncogenes [2]. It has been shown that TA and ΔN 
isoforms possess distinct, often opposing functions in 
healthy and cancerous tissues [3]. Next, it has been dem-
onstrated that the outcome of chemotherapy depends on 
the TA and ΔN isoforms ratio [4].
Unlike TP53, the gene encoding TP73 is rarely mutated 
in cancers and the functional isoforms are expressed in 
the majority of human tumors [5]. TAp73 is found inacti-
vated in cancers by binding to oncogenic ΔNp73, MDM2 
and MDMX proteins or by degradation by the ubiquitin 
ligase Itch [6, 7]. Previous studies point at the possibility 
of exploiting TAp73 as a tumor suppressor for improved 
cancer therapy. For example it has been demonstrated 
that p73 via activation of c-Jun N-terminal Kinase (JNK) 
drives the sensitivity to cisplatin in ovarian cancer cells 
independent on the p53 status [8]. Next, Nutlin3, a selec-
tive inhibitor of MDM2, stabilizes TAp73 and induces 
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TAp73-mediated apoptosis [9]. It has also been demon-
strated that simultaneous induction of proteotoxic and 
oxidative stress leads to JNK-induced phosphorylation 
of TAp73 and TAp73-mediated cell death in p53-null 
tumors [10].
Small molecule protoporphyrin IX (PpIX), is a natural 
metabolite of  δ-aminolevulinic acid, a pro-drug applied 
in clinics in photodynamic therapy of cancer (PDT) 
[11]. It has also been tested as a radiosensitizer in mouse 
mammary tumours [12]. PpIX induces HeLa cells’ apop-
tosis per se, without light excitation [13], stabilizes and 
activates wild-type p53 in human colon carcinoma cells 
[14] and binds to p73 [15].
Here, we have found that PpIX activates TAp73 in can-
cer cells lacking TP53 gene. We demonstrated that PpIX-
activated TAp73 compensates for p53 loss in cancer cells 
and induces apoptosis. The mechanism of transcriptional 
activation of TAp73 by PpIX is via inhibition of TAp73/
MDM2 and TAp73/MDMX interactions. TAp73 protein 
stabilization is achieved by disrupting TAp73/Itch com-
plex by PpIX. Furthermore, PpIX inhibits tumors growth 
in xenograft experiments.
Results
Protoporphyrin IX inhibits proliferation and induces 
apoptosis in TP53‑null cancer cells
It has been demonstrated that PpIX per se, activates wild-
type p53 by disrupting p53/MDM2 complex and induces 
p53-dependent and independent apoptosis in human 
colon cancer cells [14]. Since PpIX binds to p73 [15] we 
reasoned that p73 might play role in mediating cell death 
in p53-null cancer cells upon PpIX treatment. Here, 
in long-term proliferation assay, we showed that PpIX 
inhibits growth of several TP53-null cancer cell lines in a 
dose-dependent way (Fig.  1b). Interestingly, overexpres-
sion of TAp73α sensitized cancer cells to PpIX as shown 
in short- and long-term proliferation assays (Fig.  1c, d). 
Thus, accumulated TAp73 contributed to cancer cells’ 
susceptibility to PpIX.
Next, we assessed the genotoxicity of PpIX. The comet 
assay showed that PpIX did not induce DNA dam-
age in human colon cancer cells (Fig.  1e, f ) at effective 
concentrations against cancer cells under in  vitro con-
ditions. Importantly, western blotting demonstrated 
PARP-1 cleavage, indicating active apoptosis, only in 
cancer cells but not in normal human diploid fibroblasts 
(NHDF) after protoporphyrin IX treatment (Fig.  1g). A 
slight reduction in total PARP-1 was detected in NHDF 
after PpIX and cisplatin (CDDP) but only CDDP induced 
PARP-1 cleavage in these cells. This implies that PpIX is 
non-genotoxic and does not affect normal cells at con-
centrations tested in comparison to cisplatin.
Protoporphyrin IX induces TAp73 and its apoptotic target 
genes in TP53‑null cancer cells
To assess the potential of PpIX against other TP53-null 
human cancer cells than HCT 116 p53−/−, we employed 
human lung adenocarcinoma cells (H1299) and human 
osteosarcoma cells (Saos2). The caspase assay showed 
potent induction of apoptosis by PpIX after 6  h in all 
three cell lines tested (Fig. 2a and Additional file 1: Fig-
ure S1a). Induction of active caspases by PpIX corre-
lated with the accumulation of cleaved PARP-1 in H1299 
(Fig. 2b).
TAp73 and p53 recognize the same target genes 
involved in the apoptotic response. We found that PpIX 
at the concentrations from 1 to 5 μg/ml induces accumu-
lation of TAp73 with the concomitant upregulation of its 
apoptotic targets Noxa and PUMA on both mRNA and 
protein levels (Fig. 2c–e). At the same time we observed 
the downregulation of the oncogenic ΔN isoform of 
p73 (Fig. 2f ). The induction of TAp73 and its pro-apop-
totic targets was also detected for Nutlin3 and cisplatin 
(Fig. 2d, e, respectively). Taken together, PpIX stabilizes 
TAp73 and induces apoptosis in cancer cells lacking 
TP53 in a dose- and time-dependent manner.
PpIX‑activated TAp73 compensates for p53 loss in inducing 
apoptosis in TP53‑null cancer cells
To determine if TAp73 is critical for PpIX-induced can-
cer cells’ death, we depleted TAp73 using isoform specific 
siRNA. PpIX had no effect on the mRNA levels of TAp73 
upon the knockdown as demonstrated by real-time PCR 
(Fig. 3a).
Fig. 1 PpIX inhibits proliferation of cancer cells lacking p53. a Schematic representation of the splice variants in TP73 gene (upper panel) and 
domain structure of p73 (lower panel). TA transactivation domain, DBD DNA binding domain, OD oligomerization domain, CT C terminus. b PpIX 
induces dose‑dependent growth inhibition in a long‑term proliferation assay. c Ectopic expression of TAp73α sensitizes cells to PpIX after 24 h as 
demonstrated by WST‑1 proliferation assay. Inserted blot represents the level of expression of TAp73α. Please note that the blot has been cropped. 
Dotted line represents where the blot has been cut. The uncropped full length version is presented in Additional file 3: Figure S3a. d TAp73α 
overexpression sensitizes H1299 to PpIX‑induced inhibition of proliferation. e, f PpIX does not induce DNA damage in cancer cells at the effective 
therapeutic concentrations. g 2.5 μg/ml PpIX induces PARP‑1 cleavage in HCT 116 p53−/− but not in non‑transformed human diploid fibroblasts. 
Dotted line represents where the blot has been cut. The uncropped blot is presented in Additional file 3: Figure S3b
(See figure on next page.)
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The knockdown of TAp73 led to resistance to PpIX as 
shown in the long-term proliferation assay (Fig. 3b) and 
caspase assay (Additional file  2: Figure S2a). Next, we 
showed that silencing of TAp73 abolished PpIX-medi-
ated induction of Noxa and Puma as well as PARP-1 
cleavage (Fig.  3c, d and Additional file  2: Figure S2b). 
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In addition, the knockdown of TAp73 protected from 
induction of PARP-1 after treatment of H1299 cells with 
cisplatin (Additional file  2: Figure S2c). Thus, our data 
demonstrated that PpIX-activated TAp73 compensates 
for p53 loss and induces cancer cells’ death in the absence 
of p53.
Fig. 2 PpIX induces apoptosis and activates TAp73 in p53‑null cancer cells. a PpIX induces caspases as shown by the increase in the fluorescent 
signal in p53‑null HCT 116 p53−/− and H1299 cancer cells. b PARP‑1 cleavage in H1299 cells is induced by PpIX after 48 h treatment. c mRNA levels 
of NOXA and PUMA in H1299 cells treated with 1 μg/ml PpIX are elevated after 12 h. d, e PpIX induces TAp73 and its proapoptotic targets in H1299 
(d) and HCT 116 TP53−/− (e) cancer cells. 20 µM CDDP and 10 µM Nutlin were used as positive controls for induction of p73. The uncropped blots 
for (d) are presented in Additional file 4: Figure S4a. f PpIX downregulates ΔNp73 protein levels in HCT 116 p53−/− cancer cells
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Protoporphyrin IX activates TAp73 through the disruption 
of TAp73/MDM2 and TAp73/MDMX complex and protein 
stabilization
Our results showed that PpIX induces TAp73 transcrip-
tion activity. In cancer cells, p73 transcription activ-
ity is abrogated, among other mechanisms, by binding 
to MDM2 or MDMX (human MDM4) [16]. We have 
shown previously that PpIX inhibits p53/MDM2 com-
plex by binding to the N-terminal domain of p53 [14]. 
Since PpIX also binds to p73 [15] we addressed the ques-
tion if PpIX abrogates interactions between TAp73 and 
MDM2 by using a defined yeast-based reporter system 
[17]. Briefly, we expressed TAp73 alone or together with 
MDM2 or MDM4 in a yeast strain harboring a chromo-
somally integrated luciferase reporter containing the p53 
response element derived from the PUMA promoter. Our 
data manifested that PpIX restored the p73-dependent 
reporter in yeast strains expressing TAp73/MDM2 or 
p73/MDM4. This indicated that PpIX ablated TAp73/
MDM2 and TAp73/MDM4 interactions and promoted 
TAp73 transactivation function (Fig.  4a). To investigate 
if PpIX can inhibit TAp73/MDM2(X) interactions also in 
cancer cells, we immunoprecipitated TAp73 after treat-
ment with PpIX and blotted the membrane with MDM2 
or MDMX antibodies. Western blot showed inhibition 
of TAp73/MDM2 and p73/MDMX interactions by PpIX 
in H1299 and HCT 116 p53−/− cells (Fig. 4b, c). These 
findings are unexpected, since dual inhibitors of TAp73/
MDM2 and TAp73/MDMX interactions have not been 
described to date.
Since TAp73 protein levels (but not mRNA levels) were 
upregulated by PpIX in cancer cells (Fig. 2d, e), we per-
formed pulse-chase experiments with cycloheximide 
(CHX) to assess whether PpIX increases the half-life of 
Fig. 3 TAp73 knockdown protects cancer cells from PpIX‑induced cell death. a TAp73 knockdown with siRNA in H1299 cells as confirmed by qPCR. 
mRNA levels of TAp73 are not affected by 2.5 μg/ml PpIX. b TAp73 knockdown protects from PpIX‑induced growth inhibition in H1299 cells. c, d 
Ablation of TAp73 protects from induction of proapoptotic target Noxa by PpIX on mRNA (c) and protein levels (d)
Page 6 of 12Sznarkowska et al. Cell Div           (2018) 13:10 
TAp73 in cancer cells. We observed that PpIX decreased 
the TAp73 cellular turnover (Fig. 4d).
The key E3 ubiquitin ligase responsible for TAp73 
degradation is Itch [7]. Small molecules inhibiting Itch 
activity in cancer cells have recently been considered to 
have anticancer potential [18]. We reasoned that PpIX 
might inhibit TAp73/Itch interactions to induce TAp73 
stabilization. We then co-immunoprecipitated TAp73 
Fig. 4 PpIX ablates TAp73/MDM2, TAp73/MDMX and TAp73/Itch complexes. a PpIX rescues transcription activity of TAp73 thorough ablation of 
TAp73/MDM2 and TAp73/MDM4 interactions as assessed by yeast‑based reporter system. The t‑student test was performed for statistical analysis 
with p ≤ 0.05. * Samples are considered statistically significant. b, c Disruption of TAp73/MDM2 (b) and TAp73/MDMX and TAp73/Itch (c) binding by 
PpIX is shown in co‑immunoprecipitation experiment in HCT 116 p53−/− cells. Uncropped blots are presented in Additional file 5: Figure S5a and 
S5b. N Nutlin. d Chase experiment demonstrates stabilization of TAp73 by 1 µg/ml PpIX in H1299. NT non treated control. e TAp73/Itch interaction is 
inhibited by PpIX in H1299 by 1 µg/ml PpIX. The uncropped blots are shown in Additional file 6: Figure S6a
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and demonstrated that PpIX inhibits TAp73/Itch in both 
H1299 and HCT p53−/− cell lines and the inhibition 
was more pronounced in H1299 cells (Fig. 4c, e).
Taken together, our data showed that PpIX activates 
TAp73-dependent apoptosis at several levels, namely, 
by promoting its transcriptional activity and protecting 
from proteasomal degradation.
Protoporphyrin IX inhibits the growth of human xenograft 
tumors in mice
To assess if protoporphyrin IX will also affect the tumor 
growth in mice, we injected SCID mice bearing HCT 
116 p53−/− xenografts with sodium salt of protopor-
phyrin IX (PpIXNa). As shown in Fig. 5a, treatment with 
PpIXNa inhibited tumor growth and induced TAp73 at 
the protein level (Fig. 5b). Induction of TAp73 correlates 
with accumulation of the cleaved PARP-1. No weight loss 
was observed for PpIXNa- or vehicle-injected groups.
Discussion
It has been demonstrated that TAp73 KO mice are prone 
to carcinogen-induced tumorigenesis and that around 
35% of mice cohort develop lung adenocarcinomas [19]. 
Acute genetic ablation of ∆N isoforms triggers rapid 
regression of thymic lymphomas developed in p53-null 
mice [20]. Thus, deletion of ∆Np63 or ∆Np73 can com-
pensate for p53 tumor suppression in thymic lympho-
mas, and this occurs due to accumulation of TA isoforms 
of p63 and p73 and induction of apoptosis [21]. There-
fore, TAp73, similarly to p53, can be considered a prom-
ising therapeutic target in tumors deficient or mutant for 
TP53 gene.
Cancer-related deaths are a major health problem 
encountered today [22]. Therefore, there is an urgent 
need for the development of effective oncology drugs for 
tailored treatment of patients suffering from the meta-
static disease. The success of anti-cancer treatment relies 
on the strategy that allows inhibition of cancer drivers 
without the induction of apparent side effects. However, 
such strategies are still at the early stage of development.
The p53 reactivation suppresses established tumors 
in  vivo [23], yet this strategy is not implemented thera-
peutically. APR-246/MQ, a compound, in Phase II clini-
cal development (clinical trial ID: NCT03268382), that 
binds to cysteine residues in mutant p53 and reactivates 
its function [24] brings hope for the patients harboring 
somatic or germline TP53 gene mutations.
Li–Fraumeni Syndrome is a rare genetic syndrome 
associated with the lifetime risk of cancer development. 
It is an autosomal dominant disorder associated with ger-
mline mutations in TP53 gene. The pre-cancerous niche 
in cancer-free LFS patients is driven by TP53 mutations 
[25]. Therapeutic approaches overriding the effect of the 
niche might delay if not completely inhibit the otherwise 
heavy tumor predisposition in LFS.
Due to the above and given that approximately around 
2/3 of all human cancers harbour TP53 gene mutations 
(https ://p53.fr/), a development of a new approach to 
compensate for p53 loss, is of the outmost clinical rel-
evance. Small molecules reactivating TAp73 are of a 
special interest. Few molecules directly or indirectly 
activating TAp73 in cancer cells have been described in 
the literature. Small molecule Nutlin3, a potent inhibitor 
of p53/MDM2 interactions was found to activate p73 and 
induce p73-mediated apoptosis by disrupting p73/HDM2 
interactions in cancer cells lacking p53 [9]. Next, small 
molecule RETRA was described to specifically suppress 
mutant p53-bearing tumor cells in  vitro and in mouse 
Fig. 5 Protoporphyrin IX inhibits the growth of HCT 116 p53−/− xenograft tumors. a Inhibition of tumor growth after intravenous injections 
of PpIXNa (7.5 mg/kg/day) for day 1, 3, 6, 10 and 13. The results are shown as mean of SD (n = 5 for each group). b TAp73 is upregulated in 
PpIXNa‑treated tumors with concomitant induction of PARP‑1 cleavage
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xenografts by disrupting mtp53/p73 complex [26]. The 
widely-used genotoxic drug cisplatin (CDDP) was also 
shown to induce TAp73-mediated apoptosis in ovar-
ian cancer cells irrespective of p53 status. Recent study 
showed that TAp73 sensitizes p53-null colon cancer cells 
to bortezomib and TAp73 was shown to compensate for 
p53-loss in induction of apoptosis after drug treatment 
[27].
Our previous findings showed that protoporphyrin 
IX binds to p53 and activates p53-dependent and inde-
pendent cell death in colon cancer cells [14]. Consist-
ently, PpIX was shown to induce cancer cells’ death in 
sarcoma cells [28]. In line with our data (Fig. 1e), it was 
demonstrated that PpIX does not induce DNA damage 
but induces chromatin condensation by triggering the 
translocation of factors such as AIF from mitochondria 
to the nucleus, where it binds to the DNA and provokes 
caspase-independent chromatin changes [28].
TAp73 bears high structural and functional homol-
ogy with p53. This prompted us to study if PpIX acti-
vates TAp73 in tumors lacking functional p53. Here, we 
showed that PpIX inhibits the growth of cancer cells 
lacking p53 in a dose-dependent manner. Fluorescent-
based caspase assay indicated that the growth suppres-
sion resulted from induction of apoptosis. This is in line 
with previous study in which we observed inhibition of 
proliferation and the accumulation of HCT TP53−/− 
cells in the sub-G1 fraction of the cell cycle after PpIX 
exposure [14].
Recently, a  detailed analysis of the oligomeric state of 
TAp73 alpha by Melino’s and Dötsch’s labs revealed a 
high structure homology between p53 and p73 tetram-
ers [29]. The study thus implies that p73 can be phar-
macologically restored in a way similar to p53. This is 
supported by our previous and current findings, which 
showed that PpIX binds to p73 and induces accumula-
tion of TAp73 and its apoptotic targets in cancer cells in a 
fashion similar to p53. Using siRNA we determined that 
TAp73 is crucial for induction of apoptosis in cancer cells 
treated with PpIX. This supports the notion that pharma-
cologically restored TAp73 behaves similarly to activated 
wild-type p53 and that TAp73 can compensate for p53 
loss in cancer cells lacking TP53 gene.
To gain better insight into the mechanism of activa-
tion of TAp73 in cancer cells by PpIX, we used a yeast-
based reporter system previously developed to screen for 
activators of p53 [17]. PpIX restored TAp73-dependent 
reporter in the presence of MDM2 or MDM4, inhibi-
tors of p73 transcription activity. Thus, we concluded 
that PpIX abrogates TAp73/MDM2 and TAp73/MDMX 
interactions  which leads to the induction of its transcrip-
tion activity. In agreement with the above, PpIX inhib-
ited TAp73/MDM2 and TAp73/MDMX interactions in 
cancer cells. This finding is novel since small- molecule, 
dual inhibitors of MDM2 and MDMX have not been 
described yet. So far, only a stapled peptide therapeutic, 
ALRN-6924, inhibiting   both MDM2 and MDMX [30] 
has been developed and is currently in Phase I clinical 
trial in wild-type p53 AML and MDS (clinical trial ID: 
NCT02909972). Of note, our findings have important 
clinical relevance since the ability to disrupt the inter-
actions of TAp73 with both MDM2 and MDMX is a 
favorable therapeutic approach in tumors with MDMX 
amplification.
Since mRNA levels of p73 were not elevated by PpIX 
we reasoned, that the increase on the protein level must 
be related to the prolonged stability of TAp73 in cancer 
cells. Chase experiments confirmed that PpIX stabilizes 
TAp73 on protein level. The stabilization was a conse-
quence of disruption of interactions between TAp73 and 
E3 ubiquitin ligase, Itch in cancer cells. Furthermore, 
PpIX showed potent antitumor activity and inhibited the 
growth of HCT 116 p53−/− xenografts.
Conclusions
Taken together, our data showed that PpIX, a metabo-
lite of aminolevulinic acid, activates TAp73 by several 
mechanisms converging on activation of its transcription 
activity and protein stabilization leading to the transacti-
vation of pro-apoptotic PUMA and NOXA. Next, phar-
macologically activated TAp73 compensates for p53 loss 
and induces apoptosis in cancer cells.
The concentrations of PpIX applied herein are those 
used for  Photofrin®-PDT, a clinically approved photo-
sensitizer and an analog of PpIX, in in vitro studies [31]. 
Next, the dose of  Photofrin®, 2–2.5 mg/kg applied in the 
clinical practice is injected once during the PDT  treat-
ment. The dose of PpIX that we have applied in  the 
mouse xenograft studies is higher, however, it is expected 
since no light is needed to achieve the therapeutic effect. 
Thus, our findings, might in future lead to successful 
repurposing of porphyrins into clinical application to 
treat tumors with TP53 gene mutations.
Methods
All experiments, including protocols, were performed in 
accordance with the guidelines and regulations of Karo-
linska Institute and the University of Gdansk.
Cell culture and chemicals
The p53-deficient human colon cancer cells HCT 116 
TP53−/− [32] (a generous gift from Prof.  Bert Vogel-
stein, Johns Hopkins Medicine, Baltimore, MD, USA), 
human non-small cell lung carcinoma cell line H1299 
(ATCC) and osteosarcoma Saos2 (ATCC) cells were cul-
tured at 37 °C in a humidified incubator with 5% CO2. All 
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cell lines were maintained in Iscove’s modified Dulbecco’s 
medium (Invitrogene, Sweden) supplemented with 1 mM 
sodium pyruvate and 10% FBS (Gibco, Sweden).
Protoporphyrin IX was purchased from Sigma-Aldrich, 
Germany and dissolved in 100% DMSO (Sigma-Aldrich, 
Germany). The final concentration of DMSO in cell 
medium was 0.5%. Cisplatin (CDDP) (Sigma-Aldrich, 
Germany) was dissolved in  dH2O and used at final con-
centration 20 μM. Nutlin (Calbiochem, Sweden) was dis-
solved in DMSO and used at final concentration 10 μM.
DNA constructs and siRNA
For ectopic expression of TAp73alfa, we used pcDNA3.1-
TAp73α construct kindly provided by Prof. Matthias 
Dobbelstein, University Medical Center Göttingen, Göt-
tingen, Germany. The construct has been sequenced to 
confirm the fidelity of the transgene sequence. Transfec-
tion was performed with Lipofectamine™ 2000 (Invitro-
gen, Sweden) for 24  h according to the manufacturer’s 
protocol.
The following siRNAs were used: TAp73_318 sense: 
AGG GCA UGA CUA CAU CUG U; antisense: ACA GAU 
GUA GUC AUG CCC U and TAp73_223 sense: ACC AGA 
CAG CAC CUA CUU C; antisense: GAA GUA GGU GCU 
GUC UGG U [33]. Transfection with siRNA (10 nM) was 
performed with HiPerfect reagent (Qiagene, Germany) 
for 24  h (for WB analysis) or 48  h (for colony forma-
tion assay or qPCR analysis) following manufacturer’s 
instruction.
Growth assay
For short-term proliferation assay, HCT 116 p53−/− 
cells were seeded at  5^103/well in 96-well plate and 
transfected with either the empty vector or pcDNA3 con-
taining TAP73α sequence. After 24  h cells were treated 
with PpIX and allowed to grow for another 24  h. Cells’ 
viability was measured by WST-1 proliferation reagent 
(Roche, Switzerland).
For a long-term colony formation assay, 3000 cells/well 
were seeded into twelve-well plates and treated with indi-
cated concentrations of PpIX. The medium was changed 
after 3 h and cells were allowed to grow for 7 days. The 
colonies were stained with crystal violet reagent accord-
ing to standard protocol.
Quantitative PCR
48  h after siRNA transfection cells were harvested, 
mRNA was isolated and reverse transcribed to cDNA 
according to the manufacturer’s instructions (5 Prime, 
Hamburg, Germany; Invitrogen, Sweden). For qPCR, the 
following concentrations were used: 150  nM primers; 
10  ng cDNA; 7.5  μl 2 × master mix (Bio-Rad, Sweden); 
water to a total of 15  μl; Primers used: TAP73 forward: 
GGG AAT AAT GAG GTG GTG GG and TAP73 reverse: 
AGA TTG AAC TGG GCC ATG AC, NOXA (PMAIP1) for-
ward AAG TGC AAG TAG CTG GAA G, reverse: TGT CTC 
CAA ATC TCC TGA GT, PUMA forward: CTC AAC GCA 
CAG TAC GAG and reverse: GTC CCA TGA GAT TGT 
ACA G, GAPDH forward: TCA TTT CCT GGT ATG ACA 
ACG and reverse: ATG TGG GCC ATG AGGT.
Yeast‑based reporter system
The TAp73-dependent yeast reporter strain yLFM-
PUMA containing the luciferase cDNA cloned at the 
ADE2 locus and expressed under the control of PUMA 
promoter response element was transfected with pTSG-
p73, pLS-MDM2 (derived from pRB254, generously 
provided by Dr. R. Brachmann, University of California, 
Irvine, CA, USA) [17], or pLS-Ad-MDM4 and selected 
on double drop-out media for TRP1 and HIS3. Luciferase 
activity was measured 16  h after the shift to galactose-
containing media and the addition of PpIX (Sigma-
Aldrich, Germany), or DMSO. Presented are average 
relative light units and the standard errors obtained from 
three independent experiments each containing four bio-
logical repeats. Treatment with PpIX did not affect the 
transactivation of the reporter by TAp73 alone.
Co‑immunoprecipitation and western blotting
For TAp73/Itch and TAp73/MDMX co-IP cells were 
treated for 24 h with 1 µg/ml PpIX and 30 μM MG-132 
was added 3  h before cell harvest. For p73/MDM2 
co-IP cells were treated with PpIX or Nutlin for 24  h 
(HCT p53−/− cells). Cells for both whole cell lysates 
and immunoprecipitates were solubilized in lysis buffer: 
25 mM Tris HCl, pH 8.0, 150 mM NaCl and 1% Nonidet 
P-40 (0.5% for co-IP). For co-IP, 1 mg protein was immu-
noprecipitated with 1.5 μg of α-TAp73 rabbit polyclonal 
antibody (Bethyl Laboratories, TX, USA) or normal 
mouse IgG (Millipore, MA, USA). Immuno-complexes 
were absorbed onto 40 μl of  Dynabeads® Protein A (Inv-
itrogen, Sweden) for 5 h at 4 °C. The immunoprecipitates 
were washed with 1  ml of lysis buffer. The antibodies 
used for detection were: anti-p73 monoclonal antibodies 
[20] (IMG 246, Imgenex, UK), anti-MDM2 (Santa Cruz, 
Germany), anti-Itch (Calbiochem, Sweden), anti-MDMX 
(Bethyl Laboratories, TX, USA).
Western Blot was performed according to the stand-
ard protocol. 100 μg of total cell lysate was subjected to 
electrophoresis and the following antibodies were used 
to detect proteins: anti-TAp73 (Bethyl Laboratories, 
TX, USA), anti-Bax (Santa Cruz, Germany) anti-PUMA 
(Cell Signaling), anti-Noxa (Calbiochem, Sweden), 
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anti-PARP1/2 (Santa Cruz, Germany), anti-actin (Sigma-
Aldrich, Germany).
Caspase activation assay
Activation of caspases by PpIX was measured with 
FAM-FLICA™ Poly Caspase Assay Kit (ImmunoChem-
istry Technologies, Germany) according to manufactur-
er’s protocol. Caspase activation was monitored by the 
means of flow cytometry with BD FacsCalibur after 6 h 
treatment with PpIX.
Protein stability assay
H1299 cells were pre-treated with 1 µg/ml PpIX for 1 h 
and translation was inhibited by adding cycloheximide 
(Sigma Aldrich, Germany) to final concentration 30 µg/
ml. Cells were harvested 2, 4, 6 and 8 h after addition of 
CHX and subjected to Western blot analysis.
Comet assay
HCT p53−/− cells were seeded into 24-well plates and 
treated with PpIX (1 μg/ml and 5 μg/ml),  H2O2 (100 μM) 
was used as a positive control. Following treatment, cells 
were pelleted by centrifugation at 1500  rpm and sus-
pended in 60 μl of PBS (pH 7.4). 10 μl of cell suspension 
was mixed with 100 μl of 1% low melting agarose (Prona, 
Reducta LM, Poland) and 75 μl of this cell–agarose mix-
ture was spread on microscopic slides pre-coated with 1% 
agarose. A third layer of 0.5% low melting agarose (75 μl) 
was applied over the layer of agarose with the cell sus-
pension. Slides were incubated for 1 h in a lysis solution 
(2.5  M NaCl, 100  mM EDTA, 100  mM Tris, 1% Triton 
X- 100, pH 10). The microscopic slides were immersed 
in an alkaline buffer (300  mM NaOH, 1  mM disodium 
EDTA) for 30  min after which they were subjected to 
electrophoresis at 1 V/cm for 15 min. Subsequently slides 
were neutralized with a neutralization buffer (0.4 M Tris, 
pH 7.5) for 15  min and stained with ethidium bromide 
(20  μg/ml). Cells were analyzed under a fluorescence 
microscope (Nikon PCM-2000) using  Cometscore® soft-
ware. Images of 20 cells from three slides were analyzed. 
Densities were measured for each image in two areas: 
the whole cellular DNA and the area containing only the 
comet head. Results are presented as tail moment, which 
is the percentage of DNA in the comet tail multiplied by 
the tail length.
Animal experiments
Animal handling and housing were performed accord-
ing to the regulations of Karolinska Institutet. All ethical 
approvals have been obtained (N334/12 and N635/12). 
SCID 6-week-old female mice were injected s.c. with 
5 × 106 HCT 116 p53−/− cells in PBS. Sodium salt of 
protoporphyrin IX (Sigma-Aldrich, Germany) was pre-
pared as 100 μl injections in PBS supplemented with 10% 
DMSO. Intravenous injections were performed on day 1, 
3, 6, 10 and 13 with 7.5 mg/kg dose of PpIXNa. Vehicle 
was PBS supplemented with 10% DMSO.
Statistical analysis
Yeast assay was performed in 3 independent experiments 
with three triplicates. p < 0.05 was considered statisti-
cally relevant. The statistical significance was assessed by 
a parametric Student’s t test (for variances Fisher–Sned-
ecor’s test was applied and the normality was estimated 
with the Shapiro–Wilk’s test).
Tumor volume was analyzed according to the follow-
ing description. In order to assess the significance of drug 
mixed model analysis of repeated measures data was 
performed.
The value of Chi square statistics, degrees of freedom 
for the statistic and corresponding p value are: Chiseq 
3.53; Chi df 1; Pr 0.06. One-sided Wald test was next 
performed: t-statistics − 2.228 and p-value 0.01293. 
Thus, PpIXNa treatment significantly reduced the tumor 
volume.
Additional files
Additional file 1: Figure S1. (a) PpIX induces caspases as shown as the 
increase in the fluorescent signal in p53‑null Saos2 cells.
Additional file 2: Figure S2. (a) TAp73 depletion protects from PpIX‑
induced caspase activation in p53‑null Saos2 cells. (b) TAp73 knockdown 
ablates PpIX‑induced accumulation of PUMA and PARP‑1 cleavage in 
H1299 cells. (c) Silencing of TAp73 partially inhibits PARP‑1 cleavage in 
H1299 after CDDP treatment. Dotted line indicates sites where membrane 
was cut. The uncut blots are shown in (d).
Additional file 3: Figure S3. Uncropped versions of the blots presented 
in Fig. 1b and f, respectively. X‑sample or compound not included in this 
study.
Additional file 4: Figure S4. Uncropped versions of the blots presented 
in Fig. 2d.
Additional file 5: Figure S5. Uncropped versions of the blots presented 
in Fig. 4b, c.
Additional file 6: Figure S6. Uncropped versions of the blots presented 
in Fig. 4e.
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